Assessing the net financial benefits of employing digital endpoints in clinical trials

• Prif Awduron: Joseph A. DiMasi (Awdur), Abigail Dirks (Awdur), Zachary Smith (Awdur), Sarah Valentine (Awdur), Jennifer C. Goldsack (Awdur), Thomas Metcalfe (Awdur), Upinder Grewal (Awdur), Lada Leyens (Awdur), Ute Conradi (Awdur), Daniel Karlin (Awdur), Lesley Maloney (Awdur), Kenneth A. Getz (Awdur), Bert Hartog (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Wiley, 2024-08-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Abstract In the last few decades, developers of new drugs, biologics, and devices have increasingly leveraged digital health technologies (DHTs) to assess clinical trial digital endpoints. To our knowledge, a comprehensive assessment of the financial net benefits of digital endpoints in clinical tri...